Literature DB >> 18649875

TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide.

Zengyang Pei1, Degui Lin, Xiaoyu Song, Hui Li, Haifeng Yao.   

Abstract

Chronic inflammation promotes tumor development and progression, and Toll-like receptors (TLRs) may play an important role in this process. In this study, we found that human prostate epithelial PC3 cells constitutively express TLR4 in mRNA and protein level. lipopolysaccharide (LPS) promotes the expression and secretion of immunosuppressive cytokine TGFbeta(1) and proangiogenic factor VEGF in human prostate epithelial PC3 cells. We further elucidated that functionally activation of TLR4 is essential for the increased VEGF and TGFbeta(1) mRNA expression in the cells. In addition, after LPS stimulation, the increased expression of NF-(K)B p65 protein was also detected in human PC3 cells. Our results demonstrate that TLR4 expressed on human PC3 cells is functionally active, and may play important roles in promoting prostate cancer immune escape, survival, progression, and metastasis by inducing immunosuppressive and proangiogenic cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649875     DOI: 10.1016/j.cellimm.2008.06.007

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

1.  Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat.

Authors:  Xiang Shan Ren; Yasunori Sato; Kenichi Harada; Motoko Sasaki; Norihide Yoneda; Zhen Hua Lin; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2011-10-18       Impact factor: 4.307

2.  Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality.

Authors:  Irene M Shui; Jennifer R Stark; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Michael J Pitt; Meir J Stampfer; Rulla M Tamimi; Sara Lindstrom; Howard D Sesso; Katja Fall; Jing Ma; Peter Kraft; Edward Giovannucci; Lorelei A Mucci
Journal:  Prostate       Date:  2011-05-11       Impact factor: 4.104

Review 3.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

4.  Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.

Authors:  Fengming Lan; Xiao Yue; Gang Ren; Yingjie Wang; Tingyi Xia
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.

Authors:  Miroslava Didiasova; Dariusz Zakrzewicz; Viktor Magdolen; Chandran Nagaraj; Zoltán Bálint; Manfred Rohde; Klaus T Preissner; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2015-03-24       Impact factor: 5.157

6.  Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2.

Authors:  César Echeverría; Ignacio Montorfano; Pablo Tapia; Claudia Riedel; Claudio Cabello-Verrugio; Felipe Simon
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

7.  TLR4 is a novel determinant of the response to paclitaxel in breast cancer.

Authors:  Sandeep Rajput; Lisa D Volk-Draper; Sophia Ran
Journal:  Mol Cancer Ther       Date:  2013-05-29       Impact factor: 6.261

8.  Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.

Authors:  Fabiana Sélos Guerra; Daniel Alencar Rodrigues; Carlos Alberto Manssour Fraga; Patricia Dias Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

Review 9.  Toll-like receptor 4 activation in cancer progression and therapy.

Authors:  Alja Oblak; Roman Jerala
Journal:  Clin Dev Immunol       Date:  2011-11-03

10.  Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice.

Authors:  Ju-Hee Han; Jong-Hwan Park; Bo-Yeon Kim; Seo-Na Chang; Tae-Hyoun Kim; Jae-Hak Park; Dong-Jae Kim
Journal:  J Vet Sci       Date:  2015-03-20       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.